Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities    
Net profit/(loss) $ 21,018 $ (20,353)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 5,457 3,824
Amortization 115 253
Gain on bargain purchase   (22,155)
Share-based compensation expense 6,160 5,513
Unrealized foreign exchange (gains)/losses (266) 377
Accretion on available-for-sale debt securities (42) (633)
Other 2 663
Changes in operating assets and liabilities:    
Decrease in receivables and other operating assets 20,788 1,971
Increase/(decrease) in payables and other current liabilities 1,012 (8,801)
Increase in borrowings 454  
Decrease in deferred revenue (39,249) (41,704)
Net cash provided by/(used in) operating activities 15,449 (81,045)
Cash flows from investing activities    
Acquisition of property, plant and equipment (524) (3,565)
Acquisition of intangible assets (588) (199)
Cash from acquisition of TCR2 Therapeutics Inc.   45,264
Maturity or redemption of marketable securities   76,119
Investment in marketable securities   (67,121)
Other 11 537
Net cash (used in)/provided by investing activities (1,101) 51,035
Cash flows from financing activities    
Proceeds from issuance of borrowings, net of discount 24,500  
Proceeds from issuance of common stock from offerings, net of commissions and issuance costs 29,171 188
Proceeds from exercise of stock options 76 22
Net cash provided by financing activities 53,747 210
Effect of currency exchange rate changes on cash, cash equivalents and restricted cash (436) 398
Net increase/(decrease) in cash, cash equivalents and restricted cash 67,659 (29,402)
Cash, cash equivalents and restricted cash at start of period 147,017 109,602
Cash, cash equivalents and restricted cash at end of period $ 214,676 $ 80,200